BioSpace News Archive

Hancock Jaffe Laboratories, Inc., a developer of medical devices that restore cardiac and vascular health, announced that the first heart bypass surgery in HJLI’s first-in-human CoreoGraft study was successfully completed and the patient has been discharged from the hospital.

AXIM® Biotechnologies, Inc., an international healthcare solutions company targeting oncological and COVID-19 research, announced that it has issued a letter to its shareholders providing commentary on the Company’s recent announcements and upcoming plans.

On October 28, 2020, Yuyu Pharm initiated steps to incorporate ISO 37001 Anti-bribery management system to strengthen the company’s compliance system.

Curemark, is pleased to announce the appointment of Leigh Morgan of Seattle, WA to its Board of Directors.

MMS Holdings – an award-winning, data-focused CRO – announced that its learning arm, MMS Academy, now offers access to all of its virtual pharmaceutical industry courses through a mobile smart device application.

Omeros Corporation (Nasdaq: OMER) announced that results from its compassionate use study evaluating narsoplimab in COVID-19 patients in Italy will be shared during a virtual event being hosted today for registered participants only by ROTH Capital Partners entitled COVID-19 Therapeutics in Development: Beyond Gilead, Regeneron and Lilly . The presentation, which is part of a session on immune modulators to ameliorate COVID-19,

Building off of a successful 25 year partnership that has raised $86 million to tackle the nation’s maternal and infant health crisis, March of Dimes and Publix Super Markets, Inc. are pleased to announce their latest fundraising campaign to ensure every mom and baby have the best possible start.

Pathnostics, a diagnostic solutions company, today announced that it has launched a multiplex polymerise chain reaction (PCR) test that simultaneously detects multiple respiratory infections, including COVID-19, influenzas A/B and respiratory syncytial virus (RSV).

BetterLife Pharma, an emerging biotechnology company preparing human clinical trials of AP-003, its interferon alpha 2b inhalation therapy for the treatment of COVID-19, provided the following update regarding how it expects to overcome potential challenges of recruiting patients for human trials.

Rarecells, Inc. (USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA) positive Circulating Tumor Cells (CTC).